Aspen's $700M deal talks with GSK continue; Cubist plans $600M notes offering; Mylan adds jobs in VT;

@FiercePharma: ICYMI: Yesterday's top story: Onyx CEO will score $58M on Amgen deal. Other execs also to collect millions. More | Follow @FiercePharma

@EricPFierce: New AstraZeneca aseptic manufacturing facility at Macclesfield would add 3 dozen jobs. News | Follow @EricPFierce

@CarlyHFierce: From FierceVaccines: Will increased flushot options confuse patients? Story | Follow @CarlyHFierce

> Aspen Pharmacare says its talks to buy two GlaxoSmithKline ($GSK) thrombosis drugs and a factory for $700 million are still ongoing. Report

> Cubist Pharmaceuticals ($CBST) said it's planning a $600 million-plus offering of convertible senior notes, sending shares down on dilution worries. Report

> Mylan's ($MYL) expansion in St. Albans, VT, is expected to add 160 new jobs to its current local workforce of 591. Report

> India's Supreme Court has asked Sanofi ($SNY) to explain why it shouldn't owe Indian transaction tax on its 2009 buyout of Shantha Biotechnics. Report

> A former AstraZeneca ($AZN) president in the U.K. has joined Daresbury, England-based drug developer Proveca as chairman. Report

Medical Device News

@FierceMedDev: Siemens Dx test panel recall draws FDA's "most serious" label. Story | Follow @FierceMedDev

@MarkHFierce: FierceDiagnostics has some great new stories--check them out! FierceDiagnostics | Follow @MarkHFierce

@MichaelGFierce: Laser system gives clear, real-time image of brain tumors for surgery. Item | Follow @MichaelGFierce

> Edwards says diabetes patients may benefit from Sapien heart valve. More

> Echo Therapeutics to meet with angry shareholder. Article

> Philips joins effort to test "focused ultrasound" against metastatic bone cancer. News

Biotech News

@FierceBiotech: Troubled Rigel axes 30 staffers as it maps a comeback R&D strategy. Story | Follow @FierceBiotech

@JohnCFierce: Trending on FierceBiotech: In big setback, GlaxoSmithKline's cancer immunotherapy MAGE-A3 flunks PhIII goal. Article | Follow @JohnCFierce

@RyanMFierce: In growing diabetes market, Sanofi looks beyond iPhone for mobile glucose testing. More from FierceBiotechIT | Follow @RyanMFierce

@EmilyMFierce: Matter: A Catalog for all the World's Viruses? More from the NY Times | Follow @EmilyMFierce

> Otonomy banks $46M VC round for PhIII programs on inner-ear drugs. Story

> MacroGenics trumpets cancer immunotherapies in $60M IPO pitch. Article

> Otsuka bags Astex cancer drug programs and R&D for $886M. News

> Sanofi nabs U.S. rights to a safer aspirin in $35M Pozen deal. Report

Pharma Manufacturing News

> PhRMA, BIO, GPhA lose suit against drug-disposal law. More

> AstraZeneca plant expansion would add 3 dozen jobs. Story

> Mylan expansions roll on. Article

> Plant in Spain gets warning letter for failing to test products. News

> Merck plant gets FDA nod for bulk varicella. Report

> Last-mile thefts grow dramatically this year. Item

Vaccines News

> PATH defends itself against Indian criticisms of HPV project. Story

> CDC reports strong uptake of Merck's Gardasil in boys. More

> Researchers promise renewed push to build on Thai HIV trial success. Article

> Doctors warn plethora of flu vaccines may confuse patients. News

> FDA clears Merck plant to produce shingles vaccine ingredient. Report

> Israel may drop planned HPV vaccination program. Item

And Finally... A multitasking video game improved short-term memory and long-term focus in seniors as old as 80. Report

Suggested Articles

Creating a relevant online health user experience has its payoffs — for both the user and the brand. Here’s why.

Sanofi's new strategy delivered for the drugmaker in the third quarter as Dupixent posted blockbuster sales and flu vaccines set a revenue record.

Catalent has acquired Bone Therapeutics' cell and gene therapy site in Gosselies, Belgium, to add to its growing "center of excellence" there.